

SUPPLEMENTAL INFORMATION

For

INOLIFE TECHNOLOGIES, INC.

DEFINITIVE MERGER AGREEMENT

Dated: AUGUST 22, 2016

All information contained in this Information and Disclosure Statement has been compiled to fulfill the disclosure requirements of Rule 15c2-11 (a)(5) promulgated under the Securities and Exchange Act of 1934, as amended. The enumerated captions contained herein correspond to the sequential format as set forth in the rule.

Inolife Technologies has entered into a definitive merger agreement with 8687544 Canada Inc., the definitive merger agreement has been amended as an definitive asset purchase agreement and the number of shares increase from 30,000,000 common shares post reverse split of 1 for 30,000 to 50,000,000 common shares post reverse split of 1 for 30,000.

Inolife Technologies has not been able to obtain approval from FINRA after its second attempt to cure deficiencies. Inolife Technologies will cure its deficiencies at the New York State filings and said deficiencies may take up to 8 weeks to cure.

The parties have agreed to close the asset purchase agreement prior to the reverse split being approved and effective by FINRA. Inolife Technologies has agreed to issue 10,000,000 Preferred Series B of Inolife Technologies to N3GU Capital Ltd., and said Preferred shares Series B shall be returned to treasury and cancelled upon the effectiveness of the reverse split of 1 for 30,000 and the issuance and receipt of 50,000,000 common shares in the name of N3GU Capital Ltd. and or its nominee. Further to the business combination, a change of directors and officer is required. The new name for the Corporation shall be **Inolife Sciences Inc.**

Michael G. Wright, shall be the new President, Chief Executive Officer and Secretary of the Corporation. Kenneth Beam shall be the new Chief Financial Officer and Treasurer of the Corporation.

The new directors shall be Michael G. Wright, Joseph McClendon III, and William Cleman. William Cleman shall be the Chairman of the Board of Directors.